Prostate Cancer Clinical Trial

High Resolution PET-MRI Before Prostate Cancer HIFU

Summary

This prospective trial aims to determine if enhanced prostate imaging using two novel imaging technologies (high resolution DWI and 18F-fluciclovine PET-MRI) will detect prostate cancers not seen on standard multiparametric prostate MRI in patients considered candidates for focal HIFU.

View Full Description

Full Description

This is a prospective trial to evaluate the effectiveness of 18F-fluciclovine PET-hrMRI versus standard mpMRI at identifying prostate cancer targets for HIFU therapy.

Participants with clinically localized, unilateral high grade prostate cancer (Gleason score 7-10 prostate cancer localized to one lobe on prior biopsies) OR at high risk for having unrecognized high grade prostate cancer (overall Gleason score 6 with > half of systematic biopsy cores positive and > 50% of core involvement in at least one core), interested in HIFU would receive both a standard mpMRI and 18F-fluciclovine PET-hrMRI.

Participants would then undergo a mapping biopsy using a standard sextant template plus MRI/US-fusion targeted biopsy of any lesion suspicious lesion on mpMRI or PET-hrMRI.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Prostate biopsy consisting of ≥ 10 tissue cores sampled
PSA cT1-cT2c
Either overall gleason score >/= 7 with Gleason grade 4 or 5 component localized to one lobe (i.e. right or left) OR overall Gleason score 6 with >/= half of systematic biopsy cores positive and >/= 50% of core involvement in at least one core
Patient considering focal HIFU therapy

Exclusion Criteria:

Previous local therapy for prostate cancer
Inability to receive PET tracer
Inability to receive MRI
Suggestion of extracapsular extension or seminal vesicle invasion on imaging
Estimated creatinine clearance <45 mL/min (Cockcroft-Gault equation)
Any other condition which, in the investigator's option, may make the patient a poor candidate for participation in a clinical trial.

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

21

Study ID:

NCT03263780

Recruitment Status:

Completed

Sponsor:

Timothy J. Daskivich

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Cedars-Sinai Medical Center
Los Angeles California, 90048, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

21

Study ID:

NCT03263780

Recruitment Status:

Completed

Sponsor:


Timothy J. Daskivich

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider